Business
Retractable Technologies, Inc. Reports Results for 2025
LITTLE ELM, Texas, March 27, 2026--Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2025. Further details concerning the results of operations as well as other matters are available in Retractable’s Form 10-K filed on March 27, 2026 with the U.S. Securities and Exchange Commission.
About this update from Retractable Technologies, Inc.
[{"type":"text","content":"LITTLE ELM, Texas, March 27, 2026--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2025. Further details concerning the results of operations as well as other matters are available in Retractable’s Form 10-K filed on March 27, 2026 with the U.S. Securities and Exchange Commission.","length":376,"tagName":"p"},{"type":"text","content":"The Company’s revenues for 2025 increased 15.8%. The Company’s revenues were approximately $38.3 million in 2025 as compared to approximately $33.0 million in the prior year. Domestic revenues increased 9.7% principally due to an increase in VanishPoint® and EasyPoint® needle sales. International revenues increased 64.0% predominantly due to higher EasyPoint® needle sales. Comparability of 2025 to 2020-2023 financial results is challenging due to the unusual volume of pandemic sales in those years.","length":503,"tagName":"p"},{"type":"text","content":"The Company’s operating costs remain high since its facility expansion and, more recently, an increase in domestic production in connection with 2024-2026 tariffs. Total operating expenses were $21.2 million in 2025. The 2025 loss from operations was $21.2 million as compared to a loss from operations of $21.1 million in the prior year.","length":338,"tagName":"p"},{"type":"text","content":"The net decrease in cash for 2025 was $1.6 million. At the end of 2025, the Company’s cash position was $2.6 million, and the Company held $34.4 million in debt and equity securities.","length":183,"tagName":"p"},{"type":"text","content":"Approximately $1.8 million was incurred in tariff expense in 2025. The Company obtained 62.6% of its products from manufacturers in China. As of March 9, 2026, the prevailing tariff rate on most syringe and needle products imported from China was 120%. As foreign trade policy continues to evolve, uncertainty as to future tariff rates remains. Management expects that tariffs will continue to have a material impact on the Company’s operations and financial position.","length":468,"tagName":"p"},{"type":"text","content":"ABOUT RETRACTABLE","length":17,"tagName":"p","attribs":{}},{"type":"text","content":"Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® s...